The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.

The clinical and endocrine response to a depot preparation of the LH-RH analogue ICI 118630 (Zoladex) was assessed in 55 untreated patients with advanced prostatic cancer. Whereas gonadal androgen suppression was achieved in all patients, subjective and objective clinical response occurred in only 69%, indicated by a relief of bone pain, a decrease in the size of the primary tumour and lymph node metastases and improvement in bone scan appearances. A third of these patients, however, subsequently showed progression of their disease. Serious side effects were not encountered in this study. The depot formulation is a simple, safe and convenient method of administering Zoladex and offers an alternative treatment for metastatic prostatic cancer.

[1]  A. C. Buck,et al.  Serial Fluorine-18 bone scans in the follow-up of carcinoma of the prostate. , 1975, British journal of urology.

[2]  D. Byar,et al.  Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo , 1970, Cancer.

[3]  G. Groom.  The measurement of human gonadotrophins by radioimmunoassay. , 1977, Journal of reproduction and fertility.

[4]  R. Coutinho,et al.  Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. , 1983, British medical journal.

[5]  H. Fraser,et al.  Hypothalamic-pituitary-testicular function in rats after supraphysiological doses of a highly active LRH analogue (buserelin). , 1980, Acta endocrinologica.

[6]  S. Bloom,et al.  Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. , 1983, British medical journal.

[7]  P. Kelly,et al.  Potent inhibitory activity of [D-Leu6, Des-Gly-NH2(10)]LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat. , 1977, Endocrinology.

[8]  M. Schmidt-gollwitzer,et al.  Treatment of prostatic cancer with LH‐RH analogues , 1983, The Prostate.

[9]  W. Baum,et al.  Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. , 1950, Journal of the American Medical Association.

[10]  J. Wass,et al.  Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. , 1983, British medical journal.

[11]  F. Labrie,et al.  New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. , 1983, Journal of steroid biochemistry.

[12]  J. Trachtenberg.  The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue. , 1983, The Journal of urology.

[13]  A. Schally,et al.  Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[15]  A. Howell,et al.  TREATMENT OF ADVANCED PROSTATIC CANCER WITH LHRH ANALOGUE ICI 118630: CLINICAL RESPONSE AND HORMONAL MECHANISMS , 1983, The Lancet.

[16]  A. Schally,et al.  Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. , 1971, Biochemical and biophysical research communications.

[17]  D. Riad-fahmy,et al.  A Simple Robust Assay for Testosterone in Male Plasma Using an 125I-Radioligand and a Solid-Phase Separation Technique , 1979, Annals of clinical biochemistry.

[18]  P. Kelly,et al.  Inhibitory Effect of LHRH and Its Agonists on Testicular Gonadotrophin Receptors and Spermatogenesis in the Rat , 1978 .

[19]  W. Vale,et al.  Chronic effects of [D-Trp6-Pro9-NEt]luteinizing hormone-releasing factor on reproductive processes in the female rat. , 1978, Endocrinology.

[20]  M. Robinson,et al.  Cardiovascular complications in the treatment of prostatic carcinoma. , 1981, British journal of urology.

[21]  Resnick Mi,et al.  Treatment of stage IV carcinoma of the prostate. , 1975 .

[22]  K. Walker,et al.  THERAPEUTIC POTENTIAL OF THE LHRH AGONIST, ICI 118630, IN THE TREATMENT OF ADVANCED PROSTATIC CARCINOMA , 1983, The Lancet.

[23]  A. C. Buck,et al.  Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex). , 1984, The Journal of endocrinology.

[24]  M. Andersch,et al.  Use of p-nitrophenylphosphate as the substrate in determination of serum acid phosphatase. , 1947, American journal of clinical pathology.

[25]  A. Schally,et al.  Isolation and properties of the FSH and LH-releasing hormone. , 1971, Biochemical and biophysical research communications.